Literature DB >> 15727949

Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men.

James Gibney1, Troels Wolthers, Gudmundur Johannsson, A Margot Umpleby, Ken K Y Ho.   

Abstract

We investigated the impact of growth hormone (GH) alone, testosterone (T) alone, and combined GH and T on whole body protein metabolism. Twelve hypopituitary men participated in two studies. Study 1 compared the effects of GH alone with GH plus T, and study 2 compared the effects of T alone with GH plus T. IGF-I, resting energy expenditure (REE), and fat oxidation (F(ox)) and rates of whole body leucine appearance (R(a)), oxidation (L(ox)), and nonoxidative leucine disposal (NOLD) were measured. In study 1, GH treatment increased mean plasma IGF-I (P < 0.001). GH did not change leucine R(a) but reduced L(ox) (P < 0.02) and increased NOLD (P < 0.02). Addition of T resulted in an additional increase in IGF-I (P < 0.05), reduction in Lox (P < 0.002), and increase in NOLD (P < 0.002). In study 2, T alone did not alter IGF-I levels. T alone did not change leucine R(a) but reduced L(ox) (P < 0.01) and increased NOLD (P < 0.01). Addition of GH further reduced L(ox) (P < 0.05) and increased NOLD (P < 0.05). In both studies, combined treatments on REE and F(ox) were greater than either alone. In summary, GH-induced increase of circulating IGF-I is augmented by T, which does not increase IGF-I in the absence of GH. T and GH exerted independent and additive effects on protein metabolism, F(ox) and REE. The anabolic effects of T are independent of circulating IGF-I.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15727949     DOI: 10.1152/ajpendo.00483.2004

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  25 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

2.  Determinants of IGF1 and GH across the weight spectrum: from anorexia nervosa to obesity.

Authors:  D J Brick; A V Gerweck; E Meenaghan; E A Lawson; M Misra; P Fazeli; W Johnson; A Klibanski; K K Miller
Journal:  Eur J Endocrinol       Date:  2010-05-25       Impact factor: 6.664

3.  IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition.

Authors:  Tirissa J Reid; Zhezhen Jin; Wei Shen; Carlos M Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Jane Kostadinov; Kalmon D Post; Pamela U Freda
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

4.  Adipose Tissue Redistribution and Ectopic Lipid Deposition in Active Acromegaly and Effects of Surgical Treatment.

Authors:  Carlos M Reyes-Vidal; Hamed Mojahed; Wei Shen; Zhezhen Jin; Fernando Arias-Mendoza; Jean Carlos Fernandez; Dympna Gallagher; Jeffrey N Bruce; Kalmon D Post; Pamela U Freda
Journal:  J Clin Endocrinol Metab       Date:  2015-06-02       Impact factor: 5.958

5.  Effects of estrogen and testosterone on resting energy expenditure in older men.

Authors:  Sylvia Santosa; Sundeep Khosla; Louise K McCready; Michael D Jensen
Journal:  Obesity (Silver Spring)       Date:  2010-05-06       Impact factor: 5.002

Review 6.  Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: a meta-analysis of published observational studies.

Authors:  Jennifer C Stone; Justin Clark; Ross Cuneo; Anthony W Russell; Suhail A R Doi
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

Review 7.  Aging and hormones of the hypothalamo-pituitary axis: gonadotropic axis in men and somatotropic axes in men and women.

Authors:  Johannes D Veldhuis
Journal:  Ageing Res Rev       Date:  2008-01-05       Impact factor: 10.895

Review 8.  Growth hormone receptor modulators.

Authors:  Vita Birzniece; Akira Sata; Ken K Y Ho
Journal:  Rev Endocr Metab Disord       Date:  2009-06       Impact factor: 6.514

Review 9.  Pituitary disease mortality: is it fiction?

Authors:  Eva Marie Erfurth; Peter Siesjö; Thomas Björk-Eriksson
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

10.  Bioactive insulin-like growth factor-I in obesity.

Authors:  J Frystyk; D J Brick; A V Gerweck; A L Utz; K K Miller
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.